Immuneering Corp Net Worth
Immuneering Corp Net Worth Breakdown | IMRX |
Immuneering Corp Net Worth Analysis
Immuneering Corp's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Immuneering Corp's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Immuneering Corp's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Immuneering Corp's net worth analysis. One common approach is to calculate Immuneering Corp's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Immuneering Corp's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Immuneering Corp's net worth. This approach calculates the present value of Immuneering Corp's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Immuneering Corp's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Immuneering Corp's net worth. This involves comparing Immuneering Corp's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Immuneering Corp's net worth relative to its peers.
Enterprise Value |
|
To determine if Immuneering Corp is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Immuneering Corp's net worth research are outlined below:
| Immuneering Corp is way too risky over 90 days horizon | |
| Immuneering Corp appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (61.04 M) with profit before overhead, payroll, taxes, and interest of 158.83 K. | |
| Immuneering Corp currently holds about 128.1 M in cash with (55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.85, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Immuneering Corp has a frail financial position based on the latest SEC disclosures | |
| Roughly 24.0% of the company shares are held by company insiders | |
| Latest headline from seekingalpha.com: AptarGroup declares 0.45 dividend |
Immuneering Corp Quarterly Good Will |
|
Immuneering Corp uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Immuneering Corp. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Immuneering Corp's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Immuneering Corp Target Price Consensus
Immuneering target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Immuneering Corp's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 5 | Strong Buy |
Most Immuneering analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Immuneering stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Immuneering Corp, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationImmuneering Corp Target Price Projection
Immuneering Corp's current and average target prices are 4.13 and 11.30, respectively. The current price of Immuneering Corp is the price at which Immuneering Corp is currently trading. On the other hand, Immuneering Corp's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Immuneering Corp Market Quote on 20th of July 2025
Target Price
Analyst Consensus On Immuneering Corp Target Price
Know Immuneering Corp's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Immuneering Corp is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Immuneering Corp backward and forwards among themselves. Immuneering Corp's institutional investor refers to the entity that pools money to purchase Immuneering Corp's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bridgeway Capital Management, Llc | 2025-03-31 | 60.4 K | Tidemark Llc | 2025-03-31 | 44.4 K | Northern Trust Corp | 2025-03-31 | 39.7 K | Two Sigma Investments Llc | 2025-03-31 | 35.8 K | First Manhattan Co. Llc | 2025-03-31 | 32.3 K | Bank Of America Corp | 2025-03-31 | 28.9 K | Ubs Group Ag | 2025-03-31 | 28.6 K | Millennium Management Llc | 2025-03-31 | 23.1 K | Jane Street Group Llc | 2025-03-31 | 20.9 K | Vanguard Group Inc | 2025-03-31 | 1.1 M | Marshall Wace Asset Management Ltd | 2025-03-31 | 808 K |
Follow Immuneering Corp's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 148.62 M.Market Cap |
|
Project Immuneering Corp's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.34) | (1.27) | |
| Return On Capital Employed | (1.42) | (1.35) | |
| Return On Assets | (1.16) | (1.22) | |
| Return On Equity | (1.47) | (1.40) |
When accessing Immuneering Corp's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Immuneering Corp's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Immuneering Corp's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Immuneering Corp's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Immuneering Corp. Check Immuneering Corp's Beneish M Score to see the likelihood of Immuneering Corp's management manipulating its earnings.
Evaluate Immuneering Corp's management efficiency
Immuneering Corp has return on total asset (ROA) of (0.579) % which means that it has lost $0.579 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0248) %, meaning that it created substantial loss on money invested by shareholders. Immuneering Corp's management efficiency ratios could be used to measure how well Immuneering Corp manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -1.27 in 2025. Return On Capital Employed is likely to rise to -1.35 in 2025. At this time, Immuneering Corp's Total Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 1.4 M in 2025, whereas Net Tangible Assets are likely to drop slightly above 65.1 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.38 | 1.80 | |
| Tangible Book Value Per Share | 1.15 | 1.66 | |
| Enterprise Value Over EBITDA | (0.53) | (0.56) | |
| Price Book Value Ratio | 1.59 | 1.67 | |
| Enterprise Value Multiple | (0.53) | (0.56) | |
| Price Fair Value | 1.59 | 1.67 | |
| Enterprise Value | 34 M | 32.3 M |
The strategic initiatives led by Immuneering Corp's management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Immuneering Corp insiders, such as employees or executives, is commonly permitted as long as it does not rely on Immuneering Corp's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Immuneering Corp insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Immuneering Corp time-series forecasting models is one of many Immuneering Corp's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Immuneering Corp's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Immuneering Corp Earnings Estimation Breakdown
The calculation of Immuneering Corp's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Immuneering Corp is estimated to be -0.437 with the future projection ranging from a low of -0.575 to a high of -0.3475. Please be aware that this consensus of annual earnings estimates for Immuneering Corp is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.57 Lowest | Expected EPS | -0.35 Highest |
Immuneering Corp Earnings Projection Consensus
Suppose the current estimates of Immuneering Corp's value are higher than the current market price of the Immuneering Corp stock. In this case, investors may conclude that Immuneering Corp is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Immuneering Corp's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 6 | 82.15% | 0.0 | -0.437 | -1.97 |
Immuneering Corp Earnings per Share Projection vs Actual
Actual Earning per Share of Immuneering Corp refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Immuneering Corp predict the company's earnings will be in the future. The higher the earnings per share of Immuneering Corp, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Immuneering Corp Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Immuneering Corp, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Immuneering Corp should always be considered in relation to other companies to make a more educated investment decision.Immuneering Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Immuneering Corp's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
null | null | null | null | null | 0 | ||
2025-05-06 | 2025-03-31 | -0.49 | -0.44 | 0.05 | 10 | ||
2025-03-20 | 2024-12-31 | -0.45 | -0.58 | -0.13 | 28 | ||
2024-11-13 | 2024-09-30 | -0.5519 | -0.49 | 0.0619 | 11 | ||
2024-08-06 | 2024-06-30 | -0.52 | -0.47 | 0.05 | 9 | ||
2024-05-07 | 2024-03-31 | -0.5 | -0.49 | 0.01 | 2 | ||
2024-03-01 | 2023-12-31 | -0.47 | -0.52 | -0.05 | 10 | ||
2023-11-09 | 2023-09-30 | -0.49 | -0.43 | 0.06 | 12 | ||
2023-08-03 | 2023-06-30 | -0.53 | -0.43 | 0.1 | 18 | ||
2023-05-04 | 2023-03-31 | -0.56 | -0.51 | 0.05 | 8 | ||
2023-03-06 | 2022-12-31 | -0.58 | -0.5 | 0.08 | 13 | ||
2022-11-10 | 2022-09-30 | -0.49 | -0.49 | 0.0 | 0 | ||
2022-08-10 | 2022-06-30 | -0.52 | -0.44 | 0.08 | 15 | ||
2022-05-10 | 2022-03-31 | -0.45 | -0.49 | -0.04 | 8 | ||
2022-03-10 | 2021-12-31 | -0.39 | -0.42 | -0.03 | 7 | ||
2021-11-09 | 2021-09-30 | -0.57 | -0.47 | 0.1 | 17 | ||
2021-09-09 | 2021-06-30 | -1.44 | -1.61 | -0.17 | 11 | ||
2021-06-02 | 2021-03-31 | -1.25 | -1.26 | -0.01 | 0 | ||
2021-03-31 | 2020-12-31 | 0 | -1.2585 | -1.2585 | 0 | ||
2020-03-31 | 2019-12-31 | 0 | -0.6466 | -0.6466 | 0 |
Immuneering Corp Corporate Management
| Praveen Nair | Head VP | Profile | |
| Mallory CPA | Principal Fin | Profile | |
| Mohamedi MBA | Head Devel | Profile | |
| Leah Neufeld | Chief Officer | Profile | |
| Igor MD | Chief Officer | Profile | |
| Brett Hall | Chief Officer | Profile |
Additional Tools for Immuneering Stock Analysis
When running Immuneering Corp's price analysis, check to measure Immuneering Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immuneering Corp is operating at the current time. Most of Immuneering Corp's value examination focuses on studying past and present price action to predict the probability of Immuneering Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immuneering Corp's price. Additionally, you may evaluate how the addition of Immuneering Corp to your portfolios can decrease your overall portfolio volatility.